
The FDA issued a complete response letter to the biologics license application for ivonescimab for use in combination with chemotherapy in EGFR-mutated NSCLC.
Kartik Konduri, MD, reviews the case of a 68-year-old woman with small-cell lung cancer.
Case: A 68-Year-Old Woman with Extensive-Stage Small-Cell Lung Cancer
Initial Presentation
Clinical Workup
Treatment




